Metroxyprogesterone acetate (MPA), a first-generation progestin and a PgR agonist, is another treatment option; however, MPA also has binding affinity for other steroid receptors such as AR, and the anti-tumor mechanism in breast cancer is still unclear. This evidence concerns the gene AR and breast cancer.